On December 7, 2023 Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, reported that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) will be presented at the 65th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting held from December 9-12, 2023, in San Diego, California, USA (Press release, Seres Therapeutics, DEC 7, 2023, View Source [SID1234638276]). SER-155 is an oral, cultivated live bacterial consortia investigational therapeutic designed to prevent enteric-derived infections and resulting blood stream infections, as well as reduce the incidence of graft-versus-host disease (GvHD) by modulating immune responses in the gastrointestinal tract.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details:
Poster Title: Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Poster number: 2198
Presenter: Jonathan Peled, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
Session Date/Time: Saturday, December 9, 2023: 5:30pm – 7:30pm EST
Location: San Diego Convention Center, Halls G-H
About SER-155
SER-155 is a consortium of bacterial strains selected using Seres’ reverse translation discovery and development platform technologies. SER-155 design incorporated microbiome biomarker data from human clinical data and preclinical data from human cell-based assays and in vivo disease models. SER-155 is intended to restructure the gastrointestinal microbiome by decreasing the abundance of bacterial pathogens that can harbor antibiotic resistance, and introducing bacteria that provide immunomodulatory metabolites that can improve mucosal barrier integrity and reduce local GI inflammation. These effects are hypothesized to reduce the likelihood of pathogen translocation and subsequent bloodstream infection and GvHD.